Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

著者: Sebastian Grosicki, Maryana Simonova, Ivan Špıčka, Luděk Pour, Iryrna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Nizar J. Bahlis, Roman Hájek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Mercedes Gironella, Artur Jurczyszyn, Paweł Robak, Mónica Galli, Craig T. Wallington‐Beddoe, Atanas Radinoff, Galina Salogub, Don A. Stevens, Supratik Basu, Anna Marina Liberati, Hang Quach, Vesselina Goranova‐Marinova, Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Philippe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Donna Reece, Larry D. Anderson, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios Α. Dimopoulos, Paul G. Richardson, Sosana Delimpasi - The Lancet 2020 被引用: 324